Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This article reviews current data on the use of cognition enhancers as study aids in the student population. It identifies gaps and uncertainties in the knowledge required to make a balanced assessment of the need for some form of regulation. The review highlights the weak evidence on the prevalence of use of such drugs, especially outside the US, and the ambiguous evidence for their efficacy in a healthy population. Risks are well documented for the commonly used drugs, but poorly appreciated by users. These include not only the side-effects of the drugs themselves, but risks associated with on-line purchase, which offers no guarantees of authenticity and which for some drugs is illegal. The case for urgent action to regulate use is often linked to the belief that new and more effective drugs are likely to appear in the near future. The evidence for this is weak. However, drugs are not the only possible route to neuroenhancement and action is needed to collect more data on the impact of existing drugs, as well as new technologies, in order to guide society in making a proportionate response to the issue. This article is part of a Special Issue entitled 'Cognitive Enhancers'.

Original publication

DOI

10.1016/j.neuropharm.2012.06.016

Type

Journal article

Journal

Neuropharmacology

Publication Date

01/2013

Volume

64

Pages

588 - 595

Keywords

Cognition, Dietary Supplements, Drug-Seeking Behavior, Education, Guidelines as Topic, Humans, Memory, Short-Term, Neuropharmacology, Nonprescription Drugs, Nootropic Agents, Performance-Enhancing Substances, Professional Role, Street Drugs, Students, Test Taking Skills